4//SEC Filing
McCamish Mark Anthony 4
Accession 0001104659-23-130483
CIK 0001012477other
Filed
Dec 28, 7:00 PM ET
Accepted
Dec 29, 4:15 PM ET
Size
6.1 KB
Accession
0001104659-23-130483
Insider Transaction Report
Form 4
McCamish Mark Anthony
Director
Transactions
- Sale
ADSs
2023-12-28$14.53/sh−75,000$1,089,750→ 67,025 total(indirect: By LLC)
Footnotes (4)
- [F1]The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the Issuer; ADSs may be represented by American Depositary Receipts.
- [F2]These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.50 to $14.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]Shares held by Matthew 5 LLC. The Mark & Barbara McCamish Family Trust is the sole owner of Matthew 5 LLC, and the Reporting Person serves as its manager.
Documents
Issuer
AVADEL PHARMACEUTICALS PLC
CIK 0001012477
Entity typeother
Related Parties
1- filerCIK 0001390798
Filing Metadata
- Form type
- 4
- Filed
- Dec 28, 7:00 PM ET
- Accepted
- Dec 29, 4:15 PM ET
- Size
- 6.1 KB